Rentokil Initial (RTO) EBITDA (2021 - 2025)

On a quarterly basis, EBITDA fell 27.86% to $510.0 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.7 billion, a 48.59% decrease, with the full-year FY2025 number at $1.4 billion, up 4.76% from a year prior.

Rentokil Initial (RTO) has 5 years of EBITDA data on record, last reported at $510.0 million in Q4 2025.

  • EBITDA reached $510.0 million in Q4 2025 per RTO's latest filing, up from -$230.0 million in the prior quarter.
  • Over the last five years, EBITDA for RTO hit a ceiling of $1.0 billion in Q4 2022 and a floor of -$230.0 million in Q3 2025.
  • A 5-year average of $608.8 million and a median of $727.1 million in 2023 define the central range for EBITDA.
  • Peak YoY movement for EBITDA: increased 10.57% in 2022, then decreased 27.86% in 2025.
  • Tracing RTO's EBITDA over 5 years: stood at $911.3 million in 2021, then grew by 10.57% to $1.0 billion in 2022, then fell by 25.84% to $747.2 million in 2023, then fell by 5.38% to $707.0 million in 2024, then decreased by 27.86% to $510.0 million in 2025.
  • Business Quant data shows EBITDA for RTO at $510.0 million in Q4 2025, -$230.0 million in Q3 2025, and $707.0 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) EBITDA (Qtr)
1 Relx 81.40 Bn 81.16 Bn - 7,442.28
2 Rentokil Initial 79.56 Bn 78.10 Bn - 510.00 Mn
3 Cintas 69.26 Bn 69.08 Bn 1.45 Bn 659.90 Mn
4 Copart 33.09 Bn 28.01 Bn 971.24 Mn 388.71 Mn
5 UL Solutions 20.56 Bn 20.32 Bn 381.00 Mn 138.00 Mn
6 Global Payments 19.88 Bn 14.69 Bn 1.70 Bn -15.65 Mn
7 Rb Global 19.08 Bn 18.89 Bn 869.50 Mn 217.50 Mn
8 Aramark 13.57 Bn 13.16 Bn 426.35 Mn 219.75 Mn
9 Amentum Holdings 5.65 Bn 5.74 Bn 345.00 Mn 151.00 Mn
10 Dolby Laboratories 5.15 Bn 4.56 Bn 350.90 Mn 112.95 Mn

Historic Data

Download Data 🔒
DateValue
Dec 31, 2025 510.00 Mn
Sep 30, 2025 -230.00 Mn
Dec 31, 2024 707.00 Mn
Dec 31, 2023 747.17 Mn
Dec 31, 2022 1.01 Bn
Dec 31, 2021 911.26 Mn